October 27, 2016
Newly approved drugs push Lilly’s revenues 5% up, but net income went 3% down
The world’s leading drugmaker Eli Lilly saw a decline in net income for the third…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
October 27, 2016
Vertex starts studies for cystic fibrosis treatment
Vertex Pharmaceuticals has announced the planned initiation of two Phase 2 studies to evaluate the next-generation correctors…
October 27, 2016
Allergan to close down buying Motus, relamorelin goes to Phase 3 tests
Allergan on Thursday announced the results of Phase 2b study of the new gastroparesis…
October 27, 2016
Shire spirited up by its antiviral agent (Maribavir) Phase 2 trial results
Shire’s antiviral agent maribavir, studied in the Phase2 trial, has cleared any detectable levels of cytomegalovirus…
October 27, 2016
Allergan: changes to board leadership
Allergan has announced changes to leadership roles within its board of directors.
October 27, 2016
NIH:Gene therapy shows promise for treating Niemann-Pick disease type C1
National Institutes of Health researchers have demonstrated in mice that gene therapy may be the best method for…
October 27, 2016
Advanced Oncotherapy promotes Nicolas Serandour as new CEO
Advanced Oncotherapy has named Nicolas Serandour the new CEO…
October 27, 2016
Sanofi to participate in Zika vaccine development
Sanofi and its vaccines global business unit Sanofi Pasteur has agreed to participate…
October 26, 2016
Horizon completes acquisition of Raptor
Horizon Pharma has completed the acquisition of Raptor Pharmaceutical…
October 26, 2016
Novartis CEO sees tougher U.S. drug pricing over next three-five years
Novartis expects a more difficult pricing environment for drugs in…